Clarity Pharmaceuticals (ASX:CU6) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Clarity Pharmaceuticals's Capital Expenditure for the six months ended in Dec. 2023 was A$-0.44 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-23.62 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Clarity Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Clarity Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Capex-to-Operating-Income Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Capex-to-Operating-Income

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Clarity Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Clarity Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Capex-to-Operating-Income falls into.

Clarity Pharmaceuticals Capex-to-Operating-Income Calculation

Clarity Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.047)	/	-36.164
	=	N/A

Clarity Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.441)	/	-23.616
	=	N/A

Clarity Pharmaceuticals (ASX:CU6) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Clarity Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines